Prognostic Significance of CDKN2A/B Deletions in Acute Lymphoblastic Leukaemia: a Meta-analysis

Overview

Journal Ann Med

Publisher Informa Healthcare

Specialty General Medicine

Date 2018 Dec 29

PMID 30592434

Citations 30

Authors

Wanhua Zhang

Pu Kuang

Ting Liu

Affiliations

Soon will be listed here.

Abstract

Background: Cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) genes are frequently altered in acute lymphoblastic leukaemia (ALL) patients. The aim of this meta-analysis was to comprehensively assess the prognostic value of CDKN2A/B deletions in ALL patients.

Methods: Systematic literature review was conducted in PubMed, Embase and Cochrane databases up to July 2018. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated with fixed-effects or random-effects models.

Results: A total of thirteen studies including 2857 patients were eligible for this meta-analysis. Combined HRs suggested that CDKN2A/B deletions were poor prognostic factors for both overall survival (OS) (HR = 2.15, 95% CI 1.82-2.54) and event-free survival (EFS)/disease-free survival (DFS)/relapse-free survival (RFS) (HR = 2.16, 95% CI 1.73-2.69). The adverse impact remained significant in both adult and paediatric ALL patients, and also in subgroups by ethnicity, ALL type, detection method of CDKN2A/B deletions, statistical method and endpoint.

Conclusions: Our findings suggested that CDKN2A/B deletions were associated with poor prognosis independently in both adult and childhood ALL patients. Inclusion of CDKN2A/B status may further improve the risk stratification of ALL patients. Key Messages Although numerous studies have explored the prognostic significance of cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletions in acute lymphoblastic leukaemia (ALL) patients, the results remain conflicting. In this meta-analysis, we found that CDKN2A/B deletions were independent poor prognostic markers for both adult and paediatric ALL patients. Our findings justify the inclusion of CDKN2A/B status in the risk stratification of ALL patients.

Citing Articles

Comprehensive genomic characterization of hematologic malignancies at a pediatric tertiary care center.

Kebede A, Garfinkle E, Mathew M, Varga E, Colace S, Wheeler G Front Oncol. 2024; 14:1498409.

PMID: 39687881 PMC: 11647012. DOI: 10.3389/fonc.2024.1498409.

A meta-analysis of the prognostic significance of CDKN deletions in acute lymphoblastic leukaemia.

Hu X, Xu R, Yu S, Liu Q Ann Med. 2024; 56(1):2427365.

PMID: 39552434 PMC: 11574959. DOI: 10.1080/07853890.2024.2427365.

A comprehensive consolidation of data on the connection between CDKN2A polymorphisms and the susceptibility to childhood acute lymphoblastic leukemia.

Aghasipour M, Asadian F, Dastgheib S, Alijanpour A, Masoudi A, Barahman M Hematol Transfus Cell Ther. 2024; 46 Suppl 6:S332-S345.

PMID: 39443269 PMC: 11726081. DOI: 10.1016/j.htct.2024.05.017.

Biallelic Loss of 7q34 () and 9p21.3 (/) in Adult Ph-Negative Acute T-Lymphoblastic Leukemia.

Risinskaya N, Abdulpatakhov A, Chabaeva Y, Aleshina O, Gladysheva M, Nikulina E Int J Mol Sci. 2024; 25(19).

PMID: 39408811 PMC: 11477120. DOI: 10.3390/ijms251910482.

Germline Co-deletion of and Genes in Pleomorphic Xanthoastrocytoma: Case Report.

Agiannitopoulos K, Katseli A, Potska K, Ntogka C, Tsaousis G, Tsoulos N In Vivo. 2024; 38(4):1671-1676.

PMID: 38936911 PMC: 11215628. DOI: 10.21873/invivo.13617.

References

OConnor D, Enshaei A, Bartram J, Hancock J, Harrison C, Hough R . Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. J Clin Oncol. 2017; 36(1):34-43. PMC: 5756322. DOI: 10.1200/JCO.2017.74.0449. View

Bernt K, Hunger S . Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol. 2014; 4:54. PMC: 3971203. DOI: 10.3389/fonc.2014.00054. View

Schwab C, Chilton L, Morrison H, Jones L, Al-Shehhi H, Erhorn A . Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. Haematologica. 2013; 98(7):1081-8. PMC: 3696612. DOI: 10.3324/haematol.2013.085175. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Notta F, Mullighan C, Wang J, Poeppl A, Doulatov S, Phillips L . Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature. 2011; 469(7330):362-7. DOI: 10.1038/nature09733. View

Safavi S, Hansson M, Karlsson K, Biloglav A, Johansson B, Paulsson K . Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia. Haematologica. 2014; 100(1):55-61. PMC: 4281313. DOI: 10.3324/haematol.2014.112912. View

Pui C, Yang J, Hunger S, Pieters R, Schrappe M, Biondi A . Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol. 2015; 33(27):2938-48. PMC: 4567699. DOI: 10.1200/JCO.2014.59.1636. View

Sulong S, Moorman A, Irving J, Strefford J, Konn Z, Case M . A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood. 2008; 113(1):100-7. DOI: 10.1182/blood-2008-07-166801. View

van Zutven L, van Drunen E, de Bont J, Wattel M, den Boer M, Pieters R . CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia. Leukemia. 2005; 19(7):1281-4. DOI: 10.1038/sj.leu.2403769. View

10.

Pulte D, Jansen L, Gondos A, Katalinic A, Barnes B, Ressing M . Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS One. 2014; 9(1):e85554. PMC: 3903479. DOI: 10.1371/journal.pone.0085554. View

11.

Gutierrez M, Siraj A, Bhargava M, Ozbek U, Banavali S, Chaudhary M . Concurrent methylation of multiple genes in childhood ALL: Correlation with phenotype and molecular subgroup. Leukemia. 2003; 17(9):1845-50. DOI: 10.1038/sj.leu.2403060. View

12.

Smith L, Glaser A, Kinsey S, Greenwood D, Chilton L, Moorman A . Long-term survival after childhood acute lymphoblastic leukaemia: population-based trends in cure and relapse by clinical characteristics. Br J Haematol. 2018; 182(6):851-858. DOI: 10.1111/bjh.15424. View

13.

Kawamata N, Ogawa S, Zimmermann M, Kato M, Sanada M, Hemminki K . Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood. 2007; 111(2):776-84. PMC: 2200831. DOI: 10.1182/blood-2007-05-088310. View

14.

Agarwal M, Bakhshi S, Dwivedi S, Kabra M, Shukla R, Seth R . Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018; 65(6):e27001. DOI: 10.1002/pbc.27001. View

15.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

16.

Kim D, Moldwin R, Vignon C, Bohlander S, Suto Y, Giordano L . TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines. Blood. 1996; 88(3):785-94. View

17.

Wong I, Ng M, Huang D, Lee J . Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood. 2000; 95(6):1942-9. View

18.

Wang Y, Chen G, Cao R, Li J, He L, Guo X . Allogeneic hematopoietic stem cell transplantation improves the prognosis of p16-deleted adult patients with acute lymphoblastic leukemia. Pharmacogenomics. 2016; 18(1):77-84. DOI: 10.2217/pgs-2016-0075. View

19.

Williams R, Roussel M, Sherr C . Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2006; 103(17):6688-93. PMC: 1440588. DOI: 10.1073/pnas.0602030103. View

20.

Faderl S, Kantarjian H, Manshouri T, Chan C, Pierce S, Hays K . The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia. Clin Cancer Res. 1999; 5(7):1855-61. View